These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30261191)

  • 1. Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur.
    San-Miguel T; Navarro L; Megías J; Muñoz-Hidalgo L; Gil-Benso R; Roldán P; López-Ginés C; Cerdá-Nicolás M
    Hum Pathol; 2019 Feb; 84():105-114. PubMed ID: 30261191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.
    Maillo A; Orfao A; Espinosa AB; Sayagués JM; Merino M; Sousa P; Lara M; Tabernero MD
    Neuro Oncol; 2007 Oct; 9(4):438-46. PubMed ID: 17704362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade.
    Majchrzak-Celińska A; Paluszczak J; Szalata M; Barciszewska AM; Nowak S; Baer-Dubowska W
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1593-601. PubMed ID: 25648363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic changes with prognostic value in histologically benign meningiomas.
    Barbera S; San Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Roldan P; Gonzalez-Darder J; Cerda-Nicolas M; Lopez-Gines C
    Clin Neuropathol; 2013; 32(4):311-7. PubMed ID: 23442303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses.
    Kishida Y; Natsume A; Kondo Y; Takeuchi I; An B; Okamoto Y; Shinjo K; Saito K; Ando H; Ohka F; Sekido Y; Wakabayashi T
    Carcinogenesis; 2012 Feb; 33(2):436-41. PubMed ID: 22102699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations associated with progression and recurrence in meningiomas.
    Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
    J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
    Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
    Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biological determinations of meningioma progression and recurrence.
    Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
    PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A.
    Nakane Y; Natsume A; Wakabayashi T; Oi S; Ito M; Inao S; Saito K; Yoshida J
    J Neurosurg; 2007 Aug; 107(2):398-404. PubMed ID: 17695396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [MOLECULAR PATHOLOGY OF MENINGIOMAS].
    Murnyák B; Csonka T; Hortobágyi T
    Ideggyogy Sz; 2015 Sep; 68(9-10):292-300. PubMed ID: 26665490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
    Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
    Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
    Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
    Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas.
    Ehret F; Perez E; Teichmann D; Meier S; Geiler C; Zeus C; Franke H; Roohani S; Wasilewski D; Onken J; Vajkoczy P; Schweizer L; Kaul D; Capper D
    Acta Neuropathol Commun; 2024 May; 12(1):74. PubMed ID: 38720399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.
    Mihaila D; Jankowski M; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
    Clin Cancer Res; 2003 Oct; 9(12):4443-51. PubMed ID: 14555517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.
    Serna E; Morales JM; Mata M; Gonzalez-Darder J; San Miguel T; Gil-Benso R; Lopez-Gines C; Cerda-Nicolas M; Monleon D
    PLoS One; 2013; 8(6):e67291. PubMed ID: 23840654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The correlation of clinical and chromosomal alterations of benign meningiomas and their recurrences.
    Och W; Szmuda T; Kulbacki K; Witek K; Sikorska B; Zakrzewska M; Springer J; Reszeć J; Parda A; Liberski PP
    Neurol Neurochir Pol; 2016; 50(6):395-402. PubMed ID: 27480481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas.
    Pfisterer WK; Hank NC; Preul MC; Hendricks WP; Pueschel J; Coons SW; Scheck AC
    Neuro Oncol; 2004 Oct; 6(4):290-9. PubMed ID: 15494096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.